Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis.

ABSTRACT:

Background

Antibody-drug conjugates (ADCs) offer novel therapeutic options for advanced urological cancers, but their efficacy and safety vary across cancer types. Many non-urothelial cancer ADC trials are small, nonrandomized studies with limited validated evaluation indicators. The purpose of this study is to evaluate the efficacy and safety of ADCs across various urological cancers.

Methods

Relevant studies were identified through searches in Embase, PubMed, Web of Science, Cochrane Library, CNKI, VIP database and WanFang dataset, including randomized controlled trials, single-arm studies, and retrospective analyses on ADCs for advanced urological cancers. RoB 2.0, MINORS, and NOS were used for quality assessment, with R 4.4.0 for data analysis.

Results

This meta-a

SUBMITTER: Liu T 

PROVIDER: S-EPMC12433865 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature